Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Northern Trust Corp

Northern Trust Corp increased its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 11.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 482,815 shares of the company's stock after buying an additional 49,173 shares during the period. Northern Trust Corp owned 0.63% of Trevi Therapeutics worth $1,989,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TRVI. Summit Investment Advisors Inc. increased its holdings in Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after purchasing an additional 2,894 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics in the 4th quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Trevi Therapeutics in the 4th quarter valued at approximately $67,000. Jump Financial LLC purchased a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $89,000. Finally, Invesco Ltd. increased its stake in shares of Trevi Therapeutics by 21.2% in the fourth quarter. Invesco Ltd. now owns 23,621 shares of the company's stock worth $97,000 after acquiring an additional 4,133 shares during the period. Institutional investors own 95.76% of the company's stock.

Wall Street Analyst Weigh In

TRVI has been the topic of several recent research reports. Oppenheimer upped their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. B. Riley reaffirmed a "buy" rating and set a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, May 20th. HC Wainwright began coverage on shares of Trevi Therapeutics in a research report on Wednesday. They set a "buy" rating and a $21.00 price target on the stock. Finally, D. Boral Capital reissued a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $18.63.

Trevi Therapeutics Stock Performance

Shares of TRVI traded up $0.10 during trading hours on Friday, hitting $6.46. 369,606 shares of the stock were exchanged, compared to its average volume of 1,207,276. The stock's 50-day moving average price is $6.24 and its two-hundred day moving average price is $4.83. Trevi Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $7.39. The company has a market cap of $645.41 million, a price-to-earnings ratio of -14.64 and a beta of 0.62.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. On average, research analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Activity

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 5,263 shares of the business's stock in a transaction on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at $1,403,599.54. The trade was a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares of the company's stock, valued at $519,075. The trade was a 51.39% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 18.30% of the company's stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.